vimarsana.com
  1. Home
  2. Live Updates
  3. H3k27m Mutant Diffuse Midline Gliomas - Breaking News

H3k27m Mutant Diffuse Midline Gliomas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

United statesStephen bagleyUniversity of pennsylvania hospitalPennsylvania hospitalPenn medicinePhase 3 action trialOnc201 iH3k27m mutant diffuse midline gliomas

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

Ashley sumrallLevine cancer instituteAtrium healthUniversity of north carolina at chapel hillNorth carolinaChapel hillOnclive tvH3k27m mutant diffuse midline gliomas

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.